Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Theravance Biopharma from a "hold" to a "strong-buy," joining other firms that have recently raised ratings or price targets; MarketBeat shows a consensus of "Moderate Buy" with an average target price of $21.33.
• Shares opened at $15.08 with a 50-day/200-day moving average of $17.49/$16.91, a 52-week range of $7.90–$21.03, a market cap of about $776.5 million and a trailing P/E of 7.43.
• SVP Rhonda Farnum sold 31,067 shares at an average $13.96 on March 16, and the filing notes insiders own 6.90% while institutional investors are reported to hold 99.10% of the stock.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Sunday.

A number of other analysts also recently issued reports on the stock. Weiss Ratings upgraded shares of Theravance Biopharma from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday. Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Thursday, March 19th. BTIG Research reiterated a "buy" rating and issued a $21.00 price target on shares of Theravance Biopharma in a research note on Friday, March 20th. HC Wainwright boosted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Finally, TD Cowen increased their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a "hold" rating in a research note on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Theravance Biopharma currently has a consensus rating of "Moderate Buy" and an average target price of $21.33.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $15.08 on Friday. The company's fifty day moving average price is $17.49 and its two-hundred day moving average price is $16.91. Theravance Biopharma has a 52-week low of $7.90 and a 52-week high of $21.03. The firm has a market capitalization of $776.47 million, a PE ratio of 7.43 and a beta of 0.17.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company's stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.90% of the company's stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Quarry LP bought a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company's stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 4,662 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.